Article has no nextliveshere tags assigned

Article has no topics tags assigned

Article has no colleges tags assigned

Article has no audiences tags assigned

Article has no units tags assigned

Contacts are empty

These messages will display in edit mode only.

Fierce Biotech: Making 'cold' tumors responsive to immunotherapy

UC research points to combination therapy involving the immune system for breast cancer

Some cancers create a hostile environment that allows them to evade immune attacks. That's why many patients with cancer don't respond to immuno-oncology treatments. Scientists are looking for ways to turn these so-called “cold” tumors into “hot” ones that are susceptible to immunotherapy.

A research study by scientists at the University of Cincinnati have discovered proteins that can be targeted to overcome resistance to cancer immunotherapy in animal models. 

Syn Kok Yeo, PhD, research instructor in the department of cancer biology at the UC College of Medicine and a member in the lab of Jun-Lin Guan, PhD, the Francis Brunning Professor and Cancer Biology Department Chair, describes his research. He is a member of the UC Cancer Center.

Read the full story.

Read the UC media release.

Featured photo of stress fibers and microtubules in human breast cancer cells. Courtesy of the National Cancer Institute. 

Next Lives Here

The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.